All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Lava Therapeutics BV has raised $83 million in a series C round, enabling it to begin clinical trials of its bispecific gamma-delta T-cell engager technology, in both a hematologic and a solid tumor indication in 2021.